Sekkate Sakina, Kairouani Mouna, Abahssain Halima, Serji Badr, Boutayeb Saber, Mrabti Hind, Errihani Hassan
Institut national d'oncologie, service d'oncologie médicale, 10100 Rabat, Maroc.
Presse Med. 2012 Oct;41(10):917-26. doi: 10.1016/j.lpm.2011.11.020. Epub 2012 Jan 26.
Gastrointestinal stromal tumors (GIST) are the most common sarcomas of the gastrointestinal tract. They affect all segments of the digestive tract. They develop from the interstitial cells of Cajal. Mutations in the Kit gene is present in 86% of cases and in PDGFR gene in 15% of cases. The marker CD 117 is present in 95% of cases. Surgery is the standard treatment in localized forms. The tyrosine kinase inhibitor, imatinib is standard in first-line metastatic gastrointestinal stromal tumors, as well as adjuvant treatment after surgery. Sunitinib is the standard in second line.
胃肠道间质瘤（GIST）是胃肠道最常见的肉瘤。它们可累及消化道的所有节段。它们起源于 Cajal 间质细胞。86%的病例存在 Kit 基因突变，15%的病例存在血小板衍生生长因子受体（PDGFR）基因突变。95%的病例存在 CD 117 标志物。手术是局限性 GIST 的标准治疗方法。酪氨酸激酶抑制剂伊马替尼是一线转移性胃肠道间质瘤以及术后辅助治疗的标准用药。舒尼替尼是二线治疗的标准用药。
